The TME may contain inhibitory signals blocking immune responses and lacking cytokines like IL-15, which are essential for optimal T cell function and survival. Four clinical trials were conducted ...

Xilio Therapeutics (Nasdaq: XLO) is making significant strides in the world of immuno-oncology, with a focus on tumor-activated therapies that target cancer while minimizing the side effects often ...

The so-called tumor microenvironment (TME) is known to be the environment around the tumor and includes the encircling blood vessels, fibroblasts, signaling molecules, immune cells and the ...

The resulting T cells migrate to the TME where, once they detect their target cells, they either eliminate them directly by cytotoxic lysis or trigger the release of pro-inflammatory cytokines.

MDNA413 is an IL-13 superantagonist designed to block both IL-4 and IL-13 signaling on tumor cells and in the TME. MDNA413 has ... Superkines can provide a cytokine boost to stimulate effector ...